Antibacterial therapy of neurosyphilis: Lack of impact of new therapies

Latisha Ali, Karen Roos

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Neurosyphilis is caused by the spirochete Treponema pallidum. These organisms divide slowly, requiring long exposure to antibacterials for treatment success. In order for an antibacterial to be effective in the therapy of neurosyphilis, it must achieve treponemicidal concentrations in the CSF, have a long half-life and be given in a treatment regimen that favours compliance. Penicillin was first introduced for the treatment of syphilis in 1943, and despite interest in the use of amoxicillin, erythromycin, tetracycline, doxycycline, ceftriaxone and azithromycin, penicillin remains the only recommended antibacterial agent for neurosyphilis.

Original languageEnglish
Pages (from-to)799-802
Number of pages4
JournalCNS Drugs
Volume16
Issue number12
StatePublished - 2002

Fingerprint

Neurosyphilis
Penicillins
Treponema pallidum
Spirochaetales
Azithromycin
Ceftriaxone
Doxycycline
Amoxicillin
Erythromycin
Syphilis
Tetracycline
Compliance
Half-Life
Therapeutics
Anti-Bacterial Agents

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Neuropsychology and Physiological Psychology
  • Pharmacology

Cite this

Antibacterial therapy of neurosyphilis : Lack of impact of new therapies. / Ali, Latisha; Roos, Karen.

In: CNS Drugs, Vol. 16, No. 12, 2002, p. 799-802.

Research output: Contribution to journalArticle

@article{5bc175b01c8844e68f9ba2c62f73c91f,
title = "Antibacterial therapy of neurosyphilis: Lack of impact of new therapies",
abstract = "Neurosyphilis is caused by the spirochete Treponema pallidum. These organisms divide slowly, requiring long exposure to antibacterials for treatment success. In order for an antibacterial to be effective in the therapy of neurosyphilis, it must achieve treponemicidal concentrations in the CSF, have a long half-life and be given in a treatment regimen that favours compliance. Penicillin was first introduced for the treatment of syphilis in 1943, and despite interest in the use of amoxicillin, erythromycin, tetracycline, doxycycline, ceftriaxone and azithromycin, penicillin remains the only recommended antibacterial agent for neurosyphilis.",
author = "Latisha Ali and Karen Roos",
year = "2002",
language = "English",
volume = "16",
pages = "799--802",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "12",

}

TY - JOUR

T1 - Antibacterial therapy of neurosyphilis

T2 - Lack of impact of new therapies

AU - Ali, Latisha

AU - Roos, Karen

PY - 2002

Y1 - 2002

N2 - Neurosyphilis is caused by the spirochete Treponema pallidum. These organisms divide slowly, requiring long exposure to antibacterials for treatment success. In order for an antibacterial to be effective in the therapy of neurosyphilis, it must achieve treponemicidal concentrations in the CSF, have a long half-life and be given in a treatment regimen that favours compliance. Penicillin was first introduced for the treatment of syphilis in 1943, and despite interest in the use of amoxicillin, erythromycin, tetracycline, doxycycline, ceftriaxone and azithromycin, penicillin remains the only recommended antibacterial agent for neurosyphilis.

AB - Neurosyphilis is caused by the spirochete Treponema pallidum. These organisms divide slowly, requiring long exposure to antibacterials for treatment success. In order for an antibacterial to be effective in the therapy of neurosyphilis, it must achieve treponemicidal concentrations in the CSF, have a long half-life and be given in a treatment regimen that favours compliance. Penicillin was first introduced for the treatment of syphilis in 1943, and despite interest in the use of amoxicillin, erythromycin, tetracycline, doxycycline, ceftriaxone and azithromycin, penicillin remains the only recommended antibacterial agent for neurosyphilis.

UR - http://www.scopus.com/inward/record.url?scp=0036450335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036450335&partnerID=8YFLogxK

M3 - Article

C2 - 12421113

AN - SCOPUS:0036450335

VL - 16

SP - 799

EP - 802

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 12

ER -